Aakaar Medical Technologies Schedules H2 & FY26 Earnings Call for May 15, 2026
Aakaar Medical Technologies Limited has scheduled its H2 & FY26 earnings conference call for May 15, 2026, at 4:30 PM IST, following the Board's approval of audited financial results for the year ended March 31, 2026. The call, organised by Go India Advisors, will feature Founder & MD Dilip Meswani, CEO Rahul Sawakhande, and CFO Rakesh Parekh, with pre-registration mandatory for dial-in access. The intimation was filed under SEBI Regulation 30 and submitted to NSE on May 07, 2026.
*this image is generated using AI for illustrative purposes only.
Aakaar Medical Technologies Limited has announced the scheduling of its H2 & FY26 earnings conference call on Friday, May 15, 2026, at 4:30 PM IST. The call will be held post the announcement of the company's audited financial results for the year ended March 31, 2026, as approved by the Board of Directors at its meeting on the same date. The company had earlier communicated the Board meeting schedule through a letter dated April 01, 2026.
Earnings Call Details
The earnings call has been organised by Go India Advisors and will provide an opportunity for investors and stakeholders to engage with the company's senior leadership on its financial performance. The key company participants scheduled to be present are outlined below:
| Participant: | Designation |
|---|---|
| Mr. Dilip Meswani | Founder & Managing Director |
| Mr. Rahul Sawakhande | CEO & Executive Director |
| Mr. Rakesh Parekh | CFO |
Dial-In Information
Participants can join the call using the following dial-in details. Pre-registration is mandatory to receive call login credentials via the registration link provided by Go India Advisors.
| Region: | Dial-In Details |
|---|---|
| Universal Dial-In | +91 22 6280 1557 / +91 22 7115 8383 |
| USA Toll Free | 18667462133 |
| UK Toll Free | 08081011573 |
| Singapore Toll Free | 8001012045 |
| Hong Kong Toll Free | 800964448 |
Regulatory Compliance
The intimation has been filed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to the National Stock Exchange of India Limited on May 07, 2026, and signed by Anoopkumar Pillai, Company Secretary and Compliance Officer of Aakar Medical Technologies Ltd.
Further details and updates will be hosted on the company's website at https://aakaarmedical.in/disclosures-as-per-regulation-46-of-the-sebi-lodr-regulations/ . For additional information, stakeholders may contact Go India Advisors through Sheetal Khanduja at sheetal@goindiaadvisors.com (+91 9769364166) or Soumya Chhajed at soumya@goindiaadvisors.com (+91 8619707750).
Historical Stock Returns for Aakaar Medical Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +0.83% | -9.02% | -28.43% | -23.51% | -23.51% |
What revenue growth trajectory and margin expansion can investors expect from Aakaar Medical Technologies for FY27 given the medical devices sector's evolving regulatory landscape in India?
How might Aakaar Medical Technologies leverage its H2 FY26 performance to attract institutional investors or pursue strategic partnerships in the competitive medical technology space?
Will the company provide guidance on any planned product launches, capacity expansions, or geographic diversification during the earnings call that could drive future growth?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
